8-K/A
filed December 8, 2023, 6:59 PM ET
CIK 0001596783
other material
confidence high
sentiment negative
materiality 0.85
Catalent, Inc.: restructuring charge — Catalent revises FY2023 and Q1 FY2024 prelim results; goodwill impairment $689M
Catalent, Inc.
- FY2023 Adjusted EBITDA reduced by $17M to $697M; net loss per share widened from $(1.29) to $(1.42).
- Q4 FY2023 Adjusted EBITDA fell $17M to $122M; net loss per share increased to $(0.59) from $(0.48).
- Q1 FY2024 net loss increased $44M to $759M, including $53M tax valuation allowance; goodwill impairment adjusted to $689M.
- Q1 FY2024 Adjusted EBITDA decreased $3M to $112M; adjusted net loss per share $(0.13) vs preliminary $(0.10).
- FY2024 guidance unchanged; revisions are non-cash and included in filed 10-K and 10-Q.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Catalent, Inc. reported preliminary financial results for the fourth quarter and fiscal year ended June 30, 2023.
- Period
- the fourth quarter and fiscal year ended June 30, 2023
- Result
- preliminary results
Exact text from the filing
On August 29, 2023, the Company issued an earnings release setting forth the Company's preliminary fourth quarter and fiscal year ended June 30, 2023 financial results.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Catalent, Inc. reported preliminary financial results for the first quarter ended September 30, 2023.
- Period
- the first quarter ended September 30, 2023
- Result
- preliminary results
Exact text from the filing
In addition, on November 15, 2023, the Company issued an earnings release setting forth the Company's preliminary first quarter ended September 30, 2023 financial results.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Catalent, Inc. announced a impairment with charges of fixed asset impairment charges primarily associated with an idle facility in the Biologics segment affecting Biologics.
- Type
- impairment
- Charge
- fixed asset impairment charges primarily associated with an idle facility in the Biologics segment
- Affected area
- Biologics
Exact text from the filing
Revisions to unallocated costs represent fixed asset impairment charges primarily associated with an idle facility in the Biologics segment.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Catalent, Inc. announced a impairment with charges of $689 million of non-cash goodwill impairment charges affecting Biologics.
- Type
- impairment
- Charge
- $689 million of non-cash goodwill impairment charges
- Affected area
- Biologics
Exact text from the filing
For the three months ended September 30, 2023, unallocated costs include $689 million of non-cash goodwill impairment charges.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.